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Abstract
Background: People with diabetes and kidney disease have 
a high risk of cardiovascular events and progression of kid-
ney disease. Sodium glucose co-transporter 2 inhibitors low-
er plasma glucose by reducing the uptake of filtered glucose 
in the kidney tubule, leading to increased urinary glucose 
excretion. They have been repeatedly shown to induce mod-
est natriuresis and reduce HbA1c, blood pressure, weight, 
and albuminuria in patients with type 2 diabetes. However, 
the effects of these agents on kidney and cardiovascular 
For all the site investigators in the CREDENCE trial, see 
www.karger.com/doi/10.1159/000484633.
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events have not been extensively studied in patients with 
type 2 diabetes and established kidney disease. Methods: 
The Canagliflozin and Renal Endpoints in Diabetes with Es-
tablished Nephropathy Clinical Evaluation (CREDENCE) trial 
aims to compare the efficacy and safety of canagliflozin 
 versus placebo at preventing clinically important kidney and 
cardiovascular outcomes in patients with diabetes and es-
tablished kidney disease. CREDENCE is a randomized, dou-
ble-blind, event-driven, placebo-controlled trial set in in 34 
countries with a projected duration of ∼5.5 years and enroll-
ing 4,401 adults with type 2 diabetes, estimated glomerular 
filtration rate ≥30 to <90 mL/min/1.73 m2, and albuminuria 
(urinary albumin:creatinine ratio >300 to ≤5,000 mg/g). The 
study has 90% power to detect a 20% reduction in the risk of 
the primary outcome (α = 0.05), the composite of end-stage 
kidney disease, doubling of serum creatinine, and renal or 
cardiovascular death. Conclusion: CREDENCE will provide 
definitive evidence about the effects of canagliflozin on re-
nal (and cardiovascular) outcomes in patients with type 2 
diabetes and established kidney disease. Trial Registration: 
EudraCT number: 2013-004494-28; ClinicalTrials.gov identi-
fier: NCT02065791. © 2017 S. Karger AG, Basel
Background and Rationale
It is estimated that around the world there are cur-
rently more than 3 million people with chronic kidney 
disease (CKD) requiring renal replacement therapy, and 
that this number will increase to more than 5 million by 
2030 [1]. The most common cause of CKD in most coun-
tries is type 2 diabetes mellitus (T2DM). The estimated 
global prevalence of CKD due to diabetes is more than 
100 million [2], and much of the expected increase in kid-
ney failure is due to the rapid global increase in the prev-
alence of T2DM [3]. People affected by CKD have a re-
duced life expectancy and lower quality of life, as well as 
a substantially increased risk of cardiovascular disease 
and other adverse health outcomes [4]. The high cost of 
dialysis challenges health service budgets in both devel-
oping and developed countries. Development of treat-
ments that can prevent or delay progression of CKD in 
patients with diabetes is a research priority at both an in-
dividual and a societal level. 
Renin-angiotensin-aldosterone system blockade is 
currently the only treatment proven to prevent the de-
cline of kidney function [5] and development of kidney 
failure [6] in T2DM, based primarily on the results of 2 
parallel trials completed more than 15 years ago. While 
these agents are clearly effective in people with diabetes 
and established CKD, there is a high residual risk of dete-
riorating kidney function and other clinically important 
outcomes such as cardiovascular disease and death re-
lated to cardiovascular or kidney causes, even when the 
maximum labeled or maximally tolerated dose of these 
agents is used. Additional effective therapies are therefore 
urgently required.
Canagliflozin is a sodium glucose co-transporter 2 
(SGLT2) inhibitor that blocks glucose reabsorption in 
the proximal tubule, causing glucosuria and natriuresis. 
In patients with T2DM, canagliflozin has been shown to 
improve glycemic control, lower blood pressure (BP), 
reduce body weight, and lower albuminuria compared 
with placebo or standard care targeting glycemic control 
[7]. Canagliflozin is also generally well tolerated with 
increased incidence of adverse events (AEs) related to 
the mechanism of SGLT2 inhibition (e.g., genital my-
cotic infections, osmotic diuresis–related AEs) [8]. 
There have been reports of diabetic ketoacidosis [9], 
fractures [10], amputations [11], and acute kidney in-
jury [12] with canagliflozin; however, the incidence of 
these events was generally low across groups in clinical 
trials [8]. A recent study has shown evidence of stabiliza-
tion in kidney function with canagliflozin compared to 
the sulfonylurea glimepiride, despite similar glycemic 
control [13]. These data suggest that canagliflozin may 
protect against the progression of CKD in T2DM. This 
hypothesis is also supported by recent secondary analy-
ses from 2 cardiovascular outcome trials in the class 
showing that canagliflozin and empagliflozin stabilized 
kidney function and reduced the risk of adverse kidney 
outcomes as compared to placebo in populations de-
fined by cardiovascular disease presence and risk [14–
16]. The use of SGLT2 inhibitors is therefore a promis-
ing treatment for the prevention of kidney and cardio-
vascular outcomes in people with diabetes and 
established nephropathy, but their efficacy remains to 
be confirmed in appropriately powered, randomized 
controlled trials in this population.
Objectives
The Canagliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evaluation (CRE-
DENCE; ClinicalTrials.gov identifier: NCT02065791) 
study is designed to formally test whether canagliflozin 
 reduces the risk of kidney failure and cardiovascular events 
in patients with T2DM and markers of established kidney 
disease compared to placebo when used in addition to 
standard of care.
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Methods
CREDENCE is a randomized, double-blind, placebo-con-
trolled, parallel-group, multicenter clinical trial.
Study Setting
The study is being conducted in 695 sites in 34 countries in 
North America, Latin America, Europe, South Africa, and Asia 
Pacific (full list of countries and sites available in online suppl. Ap-
pendix 1; for all online suppl. material, see www.karger.com/
doi/10.1159/000484633).
Eligibility Criteria
The inclusion and exclusion criteria were designed to include a 
broad range of patients with diabetes at risk of progression of kid-
ney disease. Potential patients are eligible if they are aged ≥30 years 
and have a clinical diagnosis of T2DM with an HbA1c level of ≥6.5 
to ≤12.0% (except Germany, where the HbA1c range is ≥6.5 to 
≤10.5%). Patients are required to have kidney disease in the setting 
of T2DM in the absence of an alternative diagnosis to account for 
kidney pathology, although a clinical diagnosis is accepted without 
the requirement for a confirmatory kidney biopsy, in keeping with 
common clinical practice. Patients are required to have an esti-
mated glomerular filtration rate (eGFR) ≥30 to <90 mL/min/1.73 
m2 and albuminuria (urine albumin:creatinine ratio [UACR] >300 
to ≤5,000 mg/g [33.9–565.6 mg/mmol]). Patients believed to have 
nondiabetic kidney disease who have a history of treatment of kid-
ney disease with immunosuppression, or a history of treatment 
with dialysis or kidney transplantation are excluded. In order to 
ensure that the study is able to assess the impact of canagliflozin on 
the progression of CKD, the intent is that approximately 60% of the 
patient population have stage 3 CKD (rather than stage 2 CKD), 
with an eGFR of ≥30 to <60 mL/min/1.73 m2 at study entry.
All patients are required to be established on the maximum la-
beled or tolerated dose of an angiotensin-converting enzyme in-
hibitor (ACEi) or angiotensin receptor blocker (ARB) for ≥4 weeks 
prior to randomization. Combination use of an ACEi and ARB or 
use of a direct renin inhibitor is not allowed. Patients were also 
excluded if they had concomitant use of an SGLT2 inhibitor with-
in 12 weeks of randomization, current or past participation in an-
other canagliflozin study, or known allergy, hypersensitivity, or 
intolerance to canagliflozin. In addition to the kidney-related ex-
clusion criterion, patients with a history of cardiovascular events 
within the previous 12 weeks or a history of New York Heart As-
sociation class IV heart failure at any time are also excluded. Full 
exclusion criteria are summarized in online supplementary Ap-
pendix 2.
Patients are eligible if they fulfill the requirements of the inclu-
sion and exclusion criteria at the screening visit and until the ran-
domization visit.
Screening and Run-In 
Patients are prescreened on the basis of eGFR and UACR by 
medical chart review (6 months retrospective) or by prospective 
laboratory assessment to identify those with eGFR ≥30 to <90 mL/
min/1.73 m2 and UACR >300 mg/g (>33.9 mg/mmol). In coun-
tries where UACR is not routinely measured as per standard of 
care, one of the following measures is substituted: albumin excre-
tion rate >300 mg/24 h, urine protein:creatinine ratio >500 mg/g 
(>56.5 mg/mmol), or protein excretion rate >500 mg/24 h. All po-
tential patients who meet eligibility criteria at the screening visit 
may progress to the screening period. If eligibility is confirmed at 
the screening visit, patients are asked to undergo a single-blind 
placebo run-in period. The screening period, including the 2-week, 
single-blind, placebo run-in period, can be up to 10 weeks to allow 
sufficient time for the optimization of care according to local 
guidelines. The primary purpose of the run-in period is to exclude 
prior to randomization those patients unlikely to adhere to the 
long-term treatment and follow-up regimen required by the trial. 
Patients who fail to take ≥80% of the scheduled run-in treatment 
are deemed ineligible.
During the screening period, a disqualifying laboratory test 
may be repeated once at investigator discretion when there is clin-
ical reason. Patients failing entry criteria on physical or laboratory 
criteria are eligible for rescreening after appropriate clinical man-
agement at the discretion of the investigator and with the concur-
rence of the sponsor’s medical monitor. 
Randomization
Randomization is performed centrally through an interactive 
web response system using a computer-generated randomization 
schedule prepared by the study sponsor. Patients are randomly as-
signed in a 1: 1 ratio to either canagliflozin 100 mg or matching 
placebo using randomly permuted blocks with stratification by 
baseline eGFR category (≥30 to <45, ≥45 to <60, and ≥60 to <90 
mL/min/1.73 m2). 
Intervention and Control
Canagliflozin 100 mg was selected for this study due to its more 
favorable benefit to risk profile in the Phase 3 clinical development 
program compared with canagliflozin 300 mg, which demonstrat-
ed an increased risk of specific AEs (e.g., volume depletion AEs) in 
patients with CKD. Study treatment is provided in identical bottles 
of over-encapsulated canagliflozin 100 mg tablets or placebo. Pa-
tients and all study staff will remain blinded to individual treat-
ment allocation until the completion of the study. Patients take 
their study treatment once daily before the first meal of the day, 
with a log maintained with information of study capsule counts. 
Study drug administration will continue until the completion 
of the study or until the patient experiences an event that requires 
permanent cessation of the study drug. Permanent cessation is re-
quired for the following reasons: patient commences dialysis for 
end-stage kidney disease (ESKD), receives a renal transplant, be-
comes pregnant, experiences biochemically confirmed diabetic ke-
toacidosis, or is a recipient of ongoing disallowed therapy. Tempo-
rary interruption is required for subjects who develop conditions 
that are associated with amputation, such as a critical limb isch-
emia, until the condition has resolved. Restarting study medica-
tion after interruption is encouraged after careful consideration of 
the benefits and risks associated with treatment.
Patients experiencing a doubling of serum creatinine or nonfa-
tal cardiovascular events are recommended to continue study 
treatment and complete assessments at all scheduled visits. Study 
drug treatment may be temporarily interrupted for safety and/or 
tolerability reasons (such as hospitalizations for major surgical 
procedure or serious medical illness). The reasons for these inter-
ruptions are recorded if they last longer than 7 days. Patients who 
discontinue study treatment are requested to continue follow-up 
as originally planned whenever possible, or to allow abbreviated 
follow-up if the original schedule is no longer suitable.
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Background Care
Glycemic control is reinforced with diet and exercise counsel-
ing, as well as instruction in the performance of self-monitored 
fasting blood glucose assessments according to standard local 
guidelines and recorded in a study diary. Glycemic management is 
otherwise left to the discretion of the responsible physician in line 
with applicable local guidelines. Likewise, the use of all other ther-
apies is according to best practices followed throughout the course 
of the study and instituted according to local guidelines and poli-
cies. Consistent with the inclusion criteria, the combination use of 
an ACEi and ARB or use of a direct renin inhibitor is not allowed 
at any point during the study. 
Patients receive counseling on their renal and cardiovascular 
risk factor medication. Investigators review the management 
of  the patient’s lipid control and BP prior to randomization 
and  throughout the study in light of local guidelines. Sites 
are  informed approximately biannually of the proportion of 
 patients in their country/region and globally who are meeting 
glycemic control treatment targets, who reach treatment targets 
for systolic BP, and who are being treated with cardioprotective 
agents. 
Follow-Up Schedule
Postrandomization follow-up in the first 12 months is sched-
uled at 3, 13, 26, 39, and 52 weeks after randomization and there-
after at 3-month intervals (Fig. 1). The visit at 39 weeks and ev-
ery second visit thereafter are by telephone. Unscheduled blood 
tests or other safety assessment(s) can be collected at any time 
point. Patients will receive an additional telephone visit 30 days 
after the last dose of study drug. Patients who prematurely dis-
continue study treatment are encouraged to return for regular 
assessments to ensure full ascertainment of study outcomes and 
to support an intention-to-treat analysis for all outcomes.
Outcomes and Endpoint Adjudication
The primary endpoint is the composite of ESKD, doubling of 
serum creatinine, and renal or cardiovascular death (non-dia-
lyzed). The secondary and exploratory endpoints are listed in Ta-
ble 1, and the definitions of the individual endpoint components 
are listed in online supplementary Appendix 3.
All renal and cardiovascular events that are components in the 
primary and secondary composite endpoints of the study (e.g., 
ESKD, doubling of serum creatinine, death) will be adjudicated by 
an Endpoint Adjudication Committee that is blinded to treatment 
assignment. The Endpoint Adjudication Committee will also be 
responsible for adjudicating suspected endpoint events of myocar-
dial infarction (MI), stroke, hospitalized unstable angina, and hos-
pitalized congestive heart failure.
Kidney function will be assessed by calculating the eGFR using 
the CKD-EPI (CKD Epidemiology Collaboration) formula. The 
baseline average serum creatinine value is calculated as the average 
of 2 pretreatment values collected up to 4 weeks apart. Serum cre-
atinine will be measured at baseline; weeks 3, 13, and 26; and every 
6 months thereafter. Doubling of serum creatinine from baseline 
will be confirmed by a central laboratory value at least 30 days (and 
preferably within 60 days) from the first doubling from baseline 
Key entry criteria
• HbA1c ≥6.5% and ≤12.0%
• eGFR ≥30 and <90 mL/min/1.73 m2
• UACR >300 and ≤5,000 mg/g (>33.9 and ≤565.6 mg/mmol)
• Maximum tolerated labeled daily dose of an ACE inhibitor or ARB
 for ≥4 weeks prior to randomization
Pre-
screening
Wk –8 to –3
Screening
Wk –2
Run-in start
Telephone contact was made at midpoint between office visits after Wk 52.
Site visits were conducted at 26-week intervals after Wk 52.
Day 1
Baseline
Final study
visit
Wk 52Wk 39
Telephone
contact
Wk 26Wk 13Wk 3
~5.5 years
from FPI
Placebo
Canagliflozin 100 mg
Screening
• eGFR
• Albuminuria/
 proteinuria
• AHA
• Lipid
• BP
• ACE inhibitor/ARB
Run-in
R
G
lo
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l e
nd
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Prescreening Optimize medications
Fig. 1. Study design. eGFR, estimated glomerular filtration rate; AHA, anti-hyperglycemic agent; BP, blood pressure; ACE, angiotensin-
converting enzyme; ARB, angiotensin receptor blocker; HbA1c, glycated hemoglobin; R, randomization; FPI, first patient in; Wk, week; 
UACR, urinary albumin:creatinine ratio.
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detected on either local or central laboratory determinations. The 
use of medications known to impact serum creatinine levels (e.g., 
nonsteroidal anti-inflammatory drugs, trimethoprim, cimetidine, 
probenecid, aminoglycosides, amphotericin, ketoconazole, and 
clofibrate) is discouraged during the screening period and for ap-
proximately 2 weeks before any serum chemistry measurement 
during the course of the study.
To minimize intra-subject variability, first-morning-void urine 
specimens will be used, but collection is deferred during acute ill-
ness with fever, and strenuous exercise is to be avoided within 72 
hours of a planned study visit. Due to the potential risk of unblind-
ing that may occur if urine glucose levels are reported, investiga-
tors have been asked to obtain all post-baseline urinalyses through 
the central laboratory and not by a local laboratory, to avoid per-
forming local dipstick urinalysis unless required for urgent medi-
cal management (such as of diabetic ketoacidosis or other safety 
concerns), and to restrict local investigations to microscopy (rath-
er than urinalysis) when microscopy is sufficient.
In addition to the main study analyses, patients are invited to 
contribute optional fasting plasma, serum, and urine samples to 
allow for potential exploratory biomarker analyses. When local 
regulations permit, patients are also invited to contribute an op-
tional blood sample for pharmacogenomics testing. These samples 
will be stored and will be accessed to address research questions to 
be determined upon study completion.
AEs and serious AEs are being collected in accordance with good 
clinical practice and standard regulatory requirements. AEs will 
be  coded using the Medical Dictionary for Regulatory Activities 
 dictionary. During the study, AEs will be reported in conformity 
with regulatory requirements worldwide to ensure appropriate re-
Table 1. Prespecified efficacy and safety endpoints and evaluations of the CREDENCE study
Primary and secondary efficacy endpoints
Primary endpoint Composite of ESKD, doubling of serum creatinine, and renal or cardiovascular death
Secondary  
endpoints
Composite of cardiovascular death and hospitalized congestive heart failure
Cardiovascular death
All-cause death
Renal composite endpoint of ESKD, doubling of serum creatinine, and renal death
Cardiovascular composite endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalized congestive 
heart failure, and hospitalized unstable angina
Additional  
exploratory  
 endpoints
Composite endpoint of ESKD and renal or cardiovascular death
Individual components of the composite endpoints
ESKD
Doubling of serum creatinine
Renal death
Cardiovascular death
Fatal and nonfatal MI
Fatal and nonfatal stroke
Hospitalized congestive heart failure
Hospitalized unstable angina
Change in eGFR over time
Change in albuminuria over time
Safety evaluations and outcomes
Adverse events All adverse events will be collected and coded using the MedDRA from randomization until 30 days after the last 
date of blinded study medication
Adverse events of 
interest
All malignancies, fatal pancreatitis, hemorrhagic/necrotising pancreatitis, severe hypersensitivity reactions (e.g., 
angioedema, anaphylaxis, Stevens-Johnson syndrome), photosensitivity reactions, serious adverse events of hepatic 
injury, nephrotoxicity/acute kidney injury, venous thromboembolic events, fractures, diabetic ketoacidosis (and 
related adverse events including ketoacidosis, metabolic acidosis, or acidosis), amputation, and pregnancy 
Hypoglycemia All episodes of hypoglycemia (both symptomatic and asymptomatic) are recorded on a 
dedicated hypoglycemia eCRF
Safety laboratory tests Chemistry, hematology, urinalysis 
Physical examination Pulse, BP, weight
CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; ESKD, end-stage kidney di-
sease; MI, myocardial infarction; eGFR, estimated glomerular filtration rate; BP, blood pressure; MedDRA, Medical Dictionary for Regulatory 
Activities.
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porting of safety information. Prespecified AEs of interest requiring 
collection of supplemental clinical parameters include all malignan-
cies, fatal pancreatitis, hemorrhagic/necrotizing pancreatitis, severe 
hypersensitivity reactions (e.g., angioedema, anaphylaxis, Stevens-
Johnson syndrome), photosensitivity reactions, hepatic injury, 
nephrotoxicity/acute kidney injury, venous thromboembolic events, 
fractures, diabetic ketoacidosis, amputation, and pregnancy. 
Statistical Analyses
The impact of the intervention on the primary endpoint will 
be assessed by an intention-to-treat analysis using a Cox propor-
tional hazard model with an indicator variable for the treatment 
as the predictor variable and stratification of the baseline hazard 
by pretreatment eGFR (≥30 to <45, ≥45 to <60, ≥60 to <90 mL/
min/1.73 m2). The estimated treatment effect will be expressed as 
the hazard ratio and its 95% CI. Ratios of cause-specific hazards 
between the treatment groups will be obtained for each compo-
nent of the primary efficacy composite endpoint (ESKD, dou-
bling of serum creatinine, and renal or cardiovascular death), 
with stratification of the baseline hazard by the pretreatment 
eGFR group as in the analysis of the primary efficacy composite 
endpoint. 
The secondary outcomes will be analyzed in a similar fashion 
as that of the primary analysis. If superiority of canagliflozin 100 
mg over placebo for reducing the risk of the primary efficacy end-
point is established, the treatment effects in secondary endpoints 
will be tested subsequently in the following hierarchical order: (i) 
the composite endpoint of cardiovascular death and hospitalized 
congestive heart failure; (ii) the composite endpoint of cardiovas-
cular death, nonfatal MI, and nonfatal stroke (i.e., 3-point MACE); 
(iii) hospitalized congestive heart failure; (iv) the renal composite 
endpoint of ESKD, doubling of serum creatinine, and renal death; 
(v) cardiovascular death; (vi) all-cause death; and (vii) the cardio-
vascular composite endpoint of cardiovascular death, nonfatal MI, 
nonfatal stroke, hospitalized congestive heart failure, and hospital-
ized unstable angina. Statistical significance is required before test-
ing the next hypothesis in the hierarchical test procedure.
For on-treatment eGFR measurements, a linear mixed-effects 
model will be fitted to eGFR as a dependent variable, including 
treatment, stratification factor, baseline eGFR value, time (as a 
continuous variable), and treatment time interaction as fixed ef-
fects, and including subject effect as a random intercept and time 
as a random slope. The parameter of interest is the coefficient for 
treatment and time interaction term, which measures the slope dif-
ference between canagliflozin and placebo.
Safety analyses will be conducted on all patients who receive ≥1 
dose of double-blind study medication.
Powering and Sample Size
CREDENCE is an event-driven study. With a planned recruit-
ment of at least 4,200 patients, it will have 90% power to detect a 
20% relative risk reduction in the primary renal endpoint based on 
events being observed in 844 patients, and a 2-sided p value of 0.05. 
A 20% relative risk reduction is considered to be a clinically mean-
ingful effect commensurate with the risk reductions seen in studies 
of agents targeting the renin-angiotensin-aldosterone blockade [5, 
6]. Assumptions include an event rate in the placebo arm of 6.5% 
per year (similar to the rate seen in the placebo arm of the Aliskiren 
Trial in Type 2 Diabetes Using Cardio-Renal Endpoints 
 [ALTITUDE] study [17]), a premature discontinuation rate of 6% 
per year, 1% loss to follow-up, an enrollment duration of 27 
months, and a total study duration of approximately 60 months. 
An interim analysis will also be conducted by the Independent 
Data Monitoring Committee (IDMC) when primary efficacy 
events have been observed in 405 patients. The alpha spending 
function will be used, and the alpha spent to test the primary com-
posite endpoint in the interim analysis is 0.01. If the conditional 
power (based on the assumption that the hazard ratio in the re-
maining study is 0.80) is ≤10%, the study may be stopped for futil-
ity at the time of the interim analysis.
Ethics
Regulatory approval for the conduct of the trial is obtained in 
each country, and ethics approval, at every site.
Study Oversight
The CREDENCE Steering Committee is comprised of 17 inde-
pendent academics and 2 representatives of the trial sponsor. The 
Steering Committee has scientific responsibility for the design, 
conduct, data collection, analysis, and reporting of the trial. Day-
to-day trial management is provided by a Contract Research Or-
ganization, an Academic Research Organization, and the sponsor 
under the oversight of the Steering Committee. The Steering Com-
mittee will review study progress, will have full access to the trial 
database after trial completion, will conduct independent analysis 
of the main outcomes according to a prespecified Statistical Anal-
ysis Plan, and will be responsible for final publication decisions. 
An IDMC is responsible for reviewing safety in an unblinded man-
ner. In addition to reviewing safety during the study, the IDMC 
will also review the interim analysis results among other parame-
ters. A description of the roles and responsibilities of each of these 
entities is shown in online supplementary Appendix 4.
Current Status
The study recruited 4,401 participants from 34 countries be-
tween March 2014 and May 2017. Baseline characteristics for the 
enrolled patients are shown in Table 2. Of the 4,401 patients enrolled, 
66% were men and the mean age was 63.0 years. Patients had a mean 
duration of T2DM of 15.8 years and HbA1c of 8.3%. Baseline mean 
eGFR was 56.2 mL/min/1.73 m2 and median UACR was 927 mg/g.
Discussion
CREDENCE will rigorously assess whether the SGLT2 
inhibitor canagliflozin reduces the risk of a composite kid-
ney and cardiovascular outcome in individuals with dia-
betes at high risk of progression of CKD. The glucose-
lowering efficacy of canagliflozin and other SGLT2 inhib-
itors has been shown to be diminished in individuals with 
T2DM and CKD due to the renal mechanism of action; 
however, the favorable effects of agents in this class on 
multiple parameters other than glucose, including BP, 
weight, and albuminuria, may contribute to improve-
ments in renal outcomes in this population, as these pa-
rameters have been associated with reduced risk of kidney 
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disease in some studies [18, 19]. The effects of canagliflozin 
on intra-renal hemodynamics are likely an important con-
tributor to the beneficial effects on kidney function [20]. 
This may occur as part of the signaling cascade stemming 
from the blockade of SGLT2 in the proximal tubule, which 
may alter sodium reabsorption and atrial natriuretic pep-
tide release [21, 22]. A reduction in intraglomerular pres-
sure manifests clinically as an acute reduction in GFR and 
lower albuminuria, both of which have been demonstrat-
ed to occur with canagliflozin [13, 18]. 
CREDENCE will rigorously and reliably assess the ef-
fects of canagliflozin on a composite kidney outcome uti-
lizing components that have been commonly used in pre-
vious trials. The inclusion of ESKD requiring dialysis or 
transplantation has been universal in kidney outcome tri-
als. One important nuance in CREDENCE is that the 
composite outcome includes patients with an eGFR level 
that falls persistently below 15 mL/min/1.73 m2. The 
component was chosen, as it is believed to be clinically 
important, given the high rates of morbidity and ill health 
seen below this level of kidney function, and because it 
reduces some of the subjectivity seen in the timing of di-
alysis commencement [23]. Doubling of creatinine was 
chosen in contrast to lesser changes in kidney function 
(e.g., 40 or 50% reductions in eGFR) due to previous data 
showing that canagliflozin causes an acute reduction in 
eGFR, which increases the risk of a type I error for these 
lesser reductions as compared to doubling in this context 
[24]. Finally, death due to ESKD or cardiovascular disease 
was included: (i) to capture similar expected effects on 
these causes of mortality, (ii) because effects on death due 
to other causes are not expected, and (iii) because these 
causes of death share many common risk factors and 
pathways and may be difficult to differentiate. 
In providing definitive evidence on the impact of 
canagliflozin on kidney and cardiovascular outcomes 
for individuals with substantive kidney disease, 
 CREDENCE complements other large outcome trials 
designed to generate evidence on the cardiovascular 
safety of SGLT2 inhibition in individuals with T2DM 
and mild or no kidney disease (Fig.  2). These trials 
 include the completed Empagliflozin Cardiovascular 
Outcome Event Trial in T2DM Patients (EMPA-REG 
OUTCOME; NCT01131676) [14] and an integrated 
analysis of data from the CANagliflozin cardioVascular 
Assessment Study (CANVAS; NCT01032629) and 
CANVAS-R (renal endpoints; NCT01989754), which 
comprise the CANVAS Program [25]. Data supporting 
the potential benefits on kidney outcomes with SGLT2 
inhibitors have already emerged from secondary analy-
ses of the EMPA-REG OUTCOME trial [14, 15]. In ad-
dition, the CANVAS Program has recently reported ef-
fects on progression of albuminuria and a composite re-
nal endpoint [16]. Thus, there may be additional value 
in pooling data from CREDENCE and the CANVAS 
Program to gain further insights on the renal and car-
diovascular effects of canagliflozin. 
In contrast to the EMPA-REG OUTCOME and 
 CANVAS Program cardiovascular outcomes trials, 
 CREDENCE has been designed to specifically assess ef-
fects on clinically important outcomes in individuals with 
diabetes at high risk of kidney progression (Table 3). 
CKD has been associated with an increased risk of cardio-
vascular disease [26, 27], so the inclusion of an enriched 
population of patients with CKD in CREDENCE will, by 
extension, also include a large number of people with a 
high risk of cardiovascular disease. One important dis-
tinction is that the primary outcome in CREDENCE is a 
composite of renal and cardiovascular endpoints. Conse-
quently, patients were required to be on a stable regimen 
of the maximum tolerated dose of ACEi or ARB, which 
will help address the role of SGLT2 inhibition within the 
Table 2. Baseline demographic and disease characteristics
Characteristic Total (n = 4,401)
Gender, n (%)
Male 2,907 (66.1)
Female 1,494 (33.9)
Age, years 63.0±9.2
Race, n (%)
White 2,932 (66.6)
Black or African American 223 (5.1)
Asian 877 (19.9)
Other* 369 (8.4)
BMI, kg/m2 31.3±6.2
HbA1c, % 8.3±1.3
Duration of T2DM, years 15.8±8.7
eGFR, mL/min/1.73 m2 56.2±18.2
Median UACR, mg/g 927.0
Systolic BP, mmHg 140.0±15.6
Diastolic BP, mmHg 78.3±9.4
LDL-C, mmol/L 2.5±1.1
BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, 
glycated hemoglobin; eGFR, estimated glomerular filtration rate; 
UACR, urinary albumin:creatinine ratio; BP, blood pressure; LDL-
C, low-density lipoprotein cholesterol. Data are mean ± SD unless 
otherwise indicated. * Includes American Indian or Alaska Native, Native Hawaiian 
or other Pacific Islander, multiple, other, unknown, or not 
 reported.
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current standard of care for renal disease. Additionally, 
the study population in CREDENCE is at an increased 
risk of kidney events and the planned trial duration 
should be sufficiently long to observe renal-related events. 
Finally, all primary renal outcomes in CREDENCE will 
be adjudicated and doubling of serum creatinine will be 
confirmed with a repeat specimen to assess whether 
changes were sustained.
CREDENCE will also accumulate additional data on 
specific safety risks that have been associated with 
 canagliflozin treatment, such as diabetic ketoacidosis 
[9], fracture [10], amputation [11], and acute kidney 
injury [12] that will enhance the understanding of the 
balance of risks and benefits associated with use of 
canagliflozin in patients with reduced kidney function 
who may be more susceptible to adverse effects of treat-
ment.
In conclusion, the existing evidence base for cana-
gliflozin and other SGLT2 inhibitors in patients with nor-
mal or mildly impaired renal function supports a poten-
tial benefit for these therapies on renal and cardiovascular 
outcomes in patients with impaired kidney function. 
CREDENCE is specifically designed to assess the effects 
of canagliflozin on renal and cardiovascular outcomes in 
patients with T2DM at high risk of kidney disease and 
provide definitive evidence for the effect of SGLT2 inhibi-
tion in this population. If the promising preliminary data 
are confirmed, canagliflozin could lead to a substantial 
reduction in the global burden of kidney failure due to 
T2DM.
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Table 3. Key design differences among large clinical studies of SGLT2 inhibition in T2DM
Population specifics CREDENCE CANVAS Program [25] EMPA-REG OUTCOME [14]
eGFR ≥30 to <90 mL/min/1.73 m2 
(with target of ~60% with eGFR 30–<60)
(CKD-EPI)
≥30 mL/min/1.73 m2 (MDRD) ≥30 mL/min/1.73 m2 (MDRD)
UACR >300 to ≤5,000 mg/g No criteria No criteria
HbA1c ≥6.5 to ≤12.0% ≥7.0 to ≤10.5% Drug-naïve: ≥7.0 to ≤9.0%
Subjects on stable AHA: ≥7.0 to ≤10.0%
ACEi or ARB usage at enrollment Mandatory (maximum tolerated 
labeled dose stable at least 4 weeks 
prior to randomization)
No criteria (other than standard of care based on 
local practice)
No criteria
CV history inclusion No requirement ≥30 years with a history of symptomatic 
atherosclerotic coronary, cerebrovascular, or 
peripheral vascular disease, or ≥50 years with ≥2 
vascular disease risk factors (diabetes duration ≥10 
years, systolic BP >140 mmHg on ≥1 BP-lowering 
agent, current smoker, albuminuria, or HDL-C 
<1 mmol/L)
Established or high risk of CV events 
(History of MI, stroke, and/or unstable angina 
>2 months prior to participation, and/or 
multi-vessel CAD, left main CAD, single-vessel 
CAD, and/or occlusive PAD)
Design Placebo-controlled trial Placebo-controlled trials Placebo-controlled trial
Enrollment 4,401 10,142
(includes 4,330 in CANVAS, 5,812 in CANVAS-R)
7,020
Agent 100 mg canagliflozin or matching 
placebo
100 mg canagliflozin, 300 mg canagliflozin, or 
matching placebo (in CANVAS-R 100 mg 
uptitrated to 300 mg or matching placebo)
10 mg empagliflozin, 25 mg empagliflozin, or 
matching placebo
Expected duration Mean ~5.5 years Mean 5.7 years (CANVAS), and
Mean 2.1 years (CANVAS-R)* Median 3.1 years*
Primary endpoint Composite of ESKD, doubling of serum 
creatinine, and renal or CV death
Composite of CV death, nonfatal MI, and 
nonfatal stroke
Composite of CV death, nonfatal MI, and 
 nonfatal stroke
Prespecified renal clinical  
endpoints
Composite of ESKD, doubling of serum 
creatinine, and renal death
ESKD
Doubling of serum creatinine
Renal death
Composite of 40% reduction in eGFR, renal 
death, or RRT
Composite of 40% reduction in eGFR, renal death, 
RRT, or CV death
Composite of 40% reduction in eGFR, 
macroalbuminuria, renal death, or RRT
Composite of doubling of serum creatinine, renal 
death, or RRT
Composite of doubling of serum creatinine, renal 
death, RRT, or CV death
Composite of doubling of serum creatinine, 
macroalbuminuria, renal death, or RRT
Composite microvascular outcome, which 
included new/worsening nephropathy†
Composite new/worsening nephropathy and 
CV death
Doubling of creatinine with eGFR ≤45 mL/
min/1.73 m2
Post hoc renal clinical endpoints None None Composite of doubling of serum creatinine with 
eGFR ≤45 mL/min/1.73 m2, initiation of RRT, 
or death due to renal disease
Confirmation of doubling of  
serum creatinine
Doubling of serum creatinine 
confirmed on repeat specimen after 
30 days unless circumstances prevent 
this (e.g., death or dialysis) or if there 
is clear evidence that the doubling is 
related to an acute kidney injury
Doubling of serum creatinine confirmed on repeat 
specimen after 30 days unless circumstances 
prevent this (e.g., death or dialysis) or if there is 
clear evidence that the doubling is related to an 
acute kidney injury
No confirmation
Renal biochemical endpoints Changes in eGFR over time
Changes in albuminuria over time
Progression of albuminuria
Regression of albuminuria
eGFR changes over time
Changes in UACR over time 
New-onset albuminuria (UACR ≥30 mg/g)
New-onset macroalbuminuria (UACR 
≥300 mg/g)
SGLT2, sodium glucose co-transporter 2; T2DM, type 2 diabetes mellitus; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical 
 Evaluation; CANVAS, CANagliflozin cardioVascular Assessment Study; EMPA REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus 
 Patients; eGFR, estimated glomerular filtration rate; CKD-EPI, chronic kidney isease epidemiologic collaboration; MDRD, Modification of Diet in Renal Disease; UACR, urinary 
albumin:creatinine ratio; HbA1c, glycated hemoglobin; AHA, antihyperglycemic agent; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CV, car-
diovascular; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; MI,  myocardial infarction; CAD, coronary artery disease; PAD, peripheral artery disease; ESKD, end-
stage kidney disease; RRT, renal replacement therapy.* Actual follow-up periods. † New or worsening nephropathy defined in EMPA-REG OUTCOME as new-onset macroalbuminuria, doubling of serum creatinine with eGFR ≤45 mL/min/1.73 m2, initiation 
of RRT, or death due to renal disease.
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